All content for Laboratory Considerations for Clinical Trials is the property of Q Squared Solutions and is served directly from their servers
with no modification, redirects, or rehosting. The podcast is not affiliated with or endorsed by Podjoint in any way.
This podcast from Q Squared Solutions looks at factors sponsors should consider when preparing for clinical trials.
An Next Generation Sequencing Approach to Influenza Vaccine Development
Laboratory Considerations for Clinical Trials
24 minutes
6 years ago
An Next Generation Sequencing Approach to Influenza Vaccine Development
In this episode, Dr. Wayne Hogrefe and Dr. Pat Hurban discuss the use of NGS in the development and assessment of new vaccines against the influenza virus.
Topics covered include:
What health organizations are looking for that drives the selection of the next season's vaccine strains
How sequence data is used to evaluate the effectiveness of a vaccine while providing insight into the evolution of the virus
How the sequence data can inform the development of new types of vaccines and therapeutics
The prospects for a vaccine that is effective across multiple strains and multiple seasons
How NGS data differs from traditional Sanger sequencing data and what can be learned from that
You can learn more about this topic at www.q2labsolutions.com
Laboratory Considerations for Clinical Trials
This podcast from Q Squared Solutions looks at factors sponsors should consider when preparing for clinical trials.
